Ubs Oconnor LLC Autolus Therapeutics PLC Transaction History

Ubs Oconnor LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$5.39 - $7.29 $2.06 Million - $2.79 Million	-382,909 Reduced 71.07%	155,857 $994,000
Q4 2023 Feb 14, 2024	SELL	$2.13 - $6.63 $100,435 - $312,624	-47,153 Reduced 8.05%	538,766 $3.47 Million
Q3 2023 Nov 14, 2023	BUY	$2.32 - $3.36 $127,599 - $184,800	55,000 Added 10.36%	585,919 $1.37 Million
Q2 2023 Aug 14, 2023	BUY	$1.64 - $3.21 $870,707 - $1.7 Million	530,919 New	530,919 $1.26 Billion
Q1 2023 May 15, 2023	BUY	$1.75 - $2.25 $63,084 - $81,108	36,048 Added 5.0%	757,008 $1.39 Million
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $237,603 - $446,531	136,554 Added 23.37%	720,960 $0
Q3 2022 Nov 14, 2022	BUY	$2.04 - $3.76 $326 - $601	160 Added 0.03%	584,406 $1.25 Billion
Q2 2022 Aug 12, 2022	BUY	$2.04 - $4.68 $783,861 - $1.8 Million	384,246 Added 192.12%	584,246 $1.65 Million
Q1 2022 May 16, 2022	BUY	$3.52 - $5.46 $704,000 - $1.09 Million	200,000 New	200,000 $834,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $208M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.